MedinCell shares rose on the Paris Bourse on Thursday, following the announcement by its partner Teva of the successful launch in the USA of a schizophrenia treatment based on its technology.

The drug, approved by the FDA in April, has been distributed in the USA by Teva since May under the trade name Uzedy, and Teva is already very satisfied with the feedback received from healthcare professionals.

We are also seeing requests from hospitals for samples and free trials," says Richard Francis, CEO of the Israeli laboratory.

Teva also claims to have fruitful discussions with its payers, i.e. public and private insurers.

With these positive returns, the group estimates that it has already captured 40% of the long-acting risperidone market, a market estimated at four billion dollars.

For the record, MedinCell is eligible to receive commercial milestone payments of up to $105 million and royalties on net sales of the product.

Teva and MedinCell are also collaborating on olanzapine as part of a Phase 3 clinical trial due to start in January 2023, with the aim of offering a molecule as an adjunct to Uzedy for patients suffering from severe schizophrenia.

After jumping 8% this morning, MedinCell shares were slowing down, gaining just 1% by the close of trading on the Paris Bourse.

Copyright (c) 2023 CercleFinance.com. All rights reserved.